Maggot metabolites and their combinatory effects with antibiotic on Staphylococcus aureus

Annals of Clinical Microbiology and Antimicrobials

Volumn 10, Issue , 2011, Pages

  Arora, Shuchi ^a   Baptista, Carl ^b   Lim, Chu S ^b  

^a Nanyang Technological University   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; NATURAL PRODUCT; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; COMBINATION CHEMOTHERAPY; DEBRIDEMENT; DISINFECTION; DRUG POTENTIATION; DRUG SCREENING; EXTRACT; MAGGOT THERAPY; METABOLITE; MICROFLUIDICS; MINIMUM INHIBITORY CONCENTRATION; STAPHYLOCOCCUS AUREUS; WOUND HEALING; ANIMAL; BIOLOGICAL THERAPY; CHEMISTRY; DRUG EFFECT; FLY; GROWTH, DEVELOPMENT AND AGING; HUMAN; LARVA; METABOLISM; SECRETIONS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL THERAPY; BODILY SECRETIONS; CIPROFLOXACIN; DIPTERA; HUMANS; LARVA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 79551641566     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-10-6     Document Type: Article

References (35)

1. Sherman RA, Hall MJR, Thomas S. Medicinal maggots: An ancient remedy for some contemporary afflictions. Annu Rev Entomol 2000, 45:55-81. 10.1146/annurev.ento.45.1.55, 10761570.
2. Gupta A. A review of the use of maggots in wound therapy. Ann Plast Surg 2008, 60:224-227. 10.1097/SAP.0b013e318053eb5e, 18216520.
3. Turkmen A, Graham K, McGrouther DA. Therapeutic applications of the larvae for wound debridement. Journal of Plastic, Reconstructive and Aesthetic Surgery 2009, 63:184-188.
4. Parnes A, Lagan KM. Larval therapy in wound management: A review. Int J Clin Pract 2007, 61:488-493. 10.1111/j.1742-1241.2006.01238.x, 17313618.
5. Richardson M. The benefits of larval therapy in wound care. Nursing standard (Royal College of Nursing (Great Britain): 1987) 2004, 19:70. 72,74 passim.
6. Knowles A, Findlow A, Jackson N. Management of a diabetic foot ulcer using larval therapy. Nursing standard (Royal College of Nursing (Great Britain): 1987) 2001, 16:73-76.
7. Rayner K. Larval therapy in wound debridement. Professional nurse (London, England) 1999, 14:329-333.
8. Beasley WD, Hirst G. Making a meal of MRSA - The role of biosurgery in hospital-acquired infection. J Hosp Infect 2004, 56:6-9. 10.1016/j.jhin.2003.09.002, 14706264.
9. Simmons SW. The bacterial properties of excretions of the maggots of Lucilia sericata. Bull Entomol Res 1935, 26:559-563.
10. Simmons SW. A bactericidal principle in excretions of surgical maggots which destroys important etiological agents of pyogenic infections. J Bacteriol 1935, 30:253-267. 543654, 16559835.
11. Bexfield A, Nigam Y, Thomas S, Ratcliffe NA. Detection and partial characterisation of two antibacterial factors from the excretions/secretions of the medicinal maggot Lucilia sericata and their activity against methicillin-resistant Staphylococcus aureus (MRSA). Microbes and Infection 2004, 6:1297-1304. 10.1016/j.micinf.2004.08.011, 15555536.
12. Huberman L, Gollop N, Mumcuoglu KY, Breuer E, Bhusare SR, Shai Y, Galun R. Antibacterial substances of low molecular weight isolated from the blowfly, Lucilia sericata. Med Vet Entomol 2007, 21:127-131. 10.1111/j.1365-2915.2007.00668.x, 17550431.
13. Lerch K, Linde HJ, Lehn N, Grifka J. Bacteria ingestion by blowfly larvae: An in vitro study. Dermatology 2003, 207:362-366. 10.1159/000074115, 14657627.
14. Pavillard ER, Wright EA. An antibiotic from maggots. Nature 1957, 180:916-917. 10.1038/180916b0, 13483556.
15. Jaklic D, Lapanje A, Zupancic ia K, Smrke D, Gunde-Cimerman N. Selective antimicrobial activity of maggots against pathogenic bacteria. J Med Microbiol 2008, 57:617-625. 10.1099/jmm.0.47515-0, 18436596.
16. Daeschlein G, Mumcuoglu KY, Assadian O, Hoffmeister B, Kramer A. In vitro antibacterial activity of Lucilia sericata maggot secretions. Skin Pharmacology and Physiology 2007, 20:112-115. 10.1159/000097983, 17167275.
17. Mumcuoglu KY, Miller J, Mumcuoglu M, Friger M, Tarshis M. Destruction of bacteria in the digestive tract of the maggot of Lucilia sericata (Diptera: Calliphoridae). J Med Entomol 2001, 38:161-166. 10.1603/0022-2585-38.2.161, 11296817.
18. Andersen AS, Sandvang D, Schnorr KM, Kruse T, Neve S, Joergensen B, Karlsmark T, Krogfelt KA. A novel approach to the antimicrobial activity of maggot debridement therapy. J Antimicrob Chemother 2010, 65:1646-1654. 10.1093/jac/dkq165, 2904663, 20542901.
19. Cerovsky V, Zdarek J, Fucik V, Monincova L, Voburka Z, Bem R. Lucifensin, the long-sought antimicrobial factor of medicinal maggots of the blowfly Lucilia sericata. Cell Mol Life Sci 2010, 67:455-466. 10.1007/s00018-009-0194-0, 19921400.
20. Arora S, Lim CS, Baptista C. Antibacterial activity of Lucilia cuprina maggot extracts and its extraction techniques. International Journal of Integrative Biology 2010, 9:43-48.
21. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infectious Diseases 2002, 2:530-538. 10.1016/S1473-3099(02)00369-9, 12206969.
22. Sutandar A, Lim CS, Hsu LY. System for real-time monitoring of mutation-in-progress. J Appl Microbiol 2008, 104:1400-1407. 10.1111/j.1365-2672.2007.03659.x, 18298541.
23. Arora S, Lim CS, Foo JY, Sakharkar MK, Dixit P, Liu AQ, Miao JM. Microchip system for monitoring microbial physiological behaviour under drug influences. Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine 2009, 223:777-786.
24. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001, 48:5-16. 10.1093/jac/48.2.322, 11420333.
25. Schwalbe R, Steele-Moore L, Goodwin AC. Antimicrobial Susceptibility Testing Protocols 2007, CRC Press, Taylor and Francis Group.
26. Nigam Y, Bexfield A, Thomas S, Ratcliffe NA. Maggot therapy: The science and implication for CAM part II - Maggots combat infection. Evidence-based Complementary and Alternative Medicine 2006, 3:303-308. 10.1093/ecam/nel022, 1513154, 16951714.
27. Fournier B, Hooper DC. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: Novel pleiotropic effects on quinolone and coumarin activity. Antimicrob Agents Chemother 1998, 42:121-128. 10.1093/jac/42.1.121, 105466, 9449271.
28. Nakanishi N, Yoshida S, Wakebe H, Inoue M, Yamaguchi T, Mitsuhashi S. Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1991, 35:2562-2567. 245431, 1667255.
29. Antimicrobial Resistance. Fact sheet No. 194. , http://www.who.int/mediacentre/factsheets/fs194/en/
30. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004, 39:539-545. 10.1086/422458, 15356818.
31. Hoffmann JA, Hetru C. Insect defensins: Inducible antibacterial peptides. Immunol Today 1992, 13:411-415. 10.1016/0167-5699(92)90092-L, 1418378.
32. Boman HG. Innate immunity and the normal microflora. Immunol Rev 2000, 173:5-16. 10.1034/j.1600-065X.2000.917301.x, 10719663.
33. Bulet P, Hetru C, Dimarcq JL, Hoffmann D. Antimicrobial peptides in insects; structure and function. Dev Comp Immunol 1999, 23:329-344. 10.1016/S0145-305X(99)00015-4, 10426426.
34. Erdmann GR, Khalil SKW. Isolation and identification of two antibacterial agents produced by a strain of Proteus mirabilis isolated from larvae of the screwworm (Cochliomyia hominivorax) (Diptera: Calliphoridae). J Med Entomol 1986, 23:208-211.
35. Cottarel G, Wierzbowski J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol 2007, 25:547-555. 10.1016/j.tibtech.2007.09.004, 17997179.